Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Other Accumulated Expenses: 2023-2025

Historic Other Accumulated Expenses for Zenas BioPharma (ZBIO) over the last 1 years, with Sep 2025 value amounting to $580,000.

  • Zenas BioPharma's Other Accumulated Expenses rose 74.70% to $580,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $580,000, marking a year-over-year increase of 74.70%. This contributed to the annual value of $249,000 for FY2024, which is 134.91% up from last year.
  • As of Q3 2025, Zenas BioPharma's Other Accumulated Expenses stood at $580,000, which was up 14.17% from $508,000 recorded in Q2 2025.
  • Zenas BioPharma's 5-year Other Accumulated Expenses high stood at $580,000 for Q3 2025, and its period low was $106,000 during Q4 2023.
  • Over the past 3 years, Zenas BioPharma's median Other Accumulated Expenses value was $358,000 (recorded in 2024), while the average stood at $359,833.
  • Data for Zenas BioPharma's Other Accumulated Expenses shows a peak YoY surged of 134.91% (in 2024) over the last 5 years.
  • Over the past 3 years, Zenas BioPharma's Other Accumulated Expenses (Quarterly) stood at $106,000 in 2023, then surged by 134.91% to $249,000 in 2024, then skyrocketed by 74.70% to $580,000 in 2025.
  • Its Other Accumulated Expenses was $580,000 in Q3 2025, compared to $508,000 in Q2 2025 and $384,000 in Q1 2025.